Regulators of apoptosis: suitable targets for immune therapy of cancer (Q36111911)

12 August 2017

1 reference

title

Regulators of apoptosis: suitable targets for immune therapy of cancer (English)

1 reference

12 August 2017

1 reference

1 reference

1

Mads Hald Andersen

1 reference

12 August 2017

3

Per thor Straten

1 reference

12 August 2017

2

Jürgen C Becker

1 reference

12 August 2017

publication date

1 May 2005

1 reference

Nature Reviews Drug Discovery

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

399-409

1 reference

A fresh look at tumor immunosurveillance and immunotherapy.

12 August 2017

cites work

1 reference

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

Melacine: an allogeneic melanoma tumor cell lysate vaccine

21 January 2018

1 reference

Strategies for immunotherapy of cancer

21 January 2018

1 reference

Antigen-specific immunotherapy and cancer vaccines

21 January 2018

1 reference

Use of CpG oligodeoxynucleotides as immune adjuvants

21 January 2018

1 reference

New and emerging vaccination strategies for prevention and treatment of dermatological diseases

21 January 2018

1 reference

IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells

21 January 2018

1 reference

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

21 January 2018

1 reference

Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family

21 January 2018

1 reference

Apoptosis-based therapies

21 January 2018

1 reference

Apoptosis and cancer chemotherapy.

21 January 2018

1 reference

Molecular mechanisms of drug resistance

21 January 2018

1 reference

Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy

21 January 2018

1 reference

Bcl-xL antisense oligonucleotides radiosensitise colon cancer cells

21 January 2018

1 reference

BH3-Only proteins-essential initiators of apoptotic cell death

21 January 2018

1 reference

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix

21 January 2018

1 reference

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

21 January 2018

1 reference

Apoptosis-targeted therapies for cancer

21 January 2018

1 reference

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

21 January 2018

1 reference

Validating survivin as a cancer therapeutic target

21 January 2018

1 reference

Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer

21 January 2018

1 reference

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

21 January 2018

1 reference

Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting

21 January 2018

1 reference

Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma

21 January 2018

1 reference

Analysis of human transcriptomes.

21 January 2018

1 reference

Cell division and cell survival in the absence of survivin

21 January 2018

1 reference

Control of apoptosis and mitotic spindle checkpoint by survivin

21 January 2018

1 reference

Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells

21 January 2018

1 reference

RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy

21 January 2018

1 reference

Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

21 January 2018

1 reference

Livin, a novel inhibitor of apoptosis protein family member

21 January 2018

1 reference

ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas

21 January 2018

1 reference

Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern

21 January 2018

1 reference

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction

21 January 2018

1 reference

Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP.

21 January 2018

1 reference

The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses

21 January 2018

1 reference

Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.

21 January 2018

1 reference

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

21 January 2018

1 reference

BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy

21 January 2018

1 reference

Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1

21 January 2018

1 reference

The role of the Bcl-2 protein family in cancer

21 January 2018

1 reference

Immunogenicity of Bcl-2 in patients with cancer

21 January 2018

1 reference

Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia

21 January 2018

1 reference

Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action

21 January 2018

1 reference

Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.

21 January 2018

1 reference

Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.

21 January 2018

1 reference

Interleukin-7: master regulator of peripheral T-cell homeostasis?

21 January 2018

1 reference

Antiangiogenic gene therapy of cancer: recent developments

21 January 2018

1 reference

VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition

21 January 2018

1 reference

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

21 January 2018

1 reference

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB

21 January 2018

1 reference

Design and evaluation of antigen-specific vaccination strategies against cancer.

21 January 2018

1 reference

Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses

21 January 2018

1 reference

The human T cell receptor in health and disease

21 January 2018

1 reference

Dendritic cells: immunological sentinels with a central role in health and disease.

21 January 2018

1 reference

T-cell recognition of melanoma-associated antigens

21 January 2018

1 reference

Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes

21 January 2018

1 reference

Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model

21 January 2018

1 reference

Synergy between tumor immunotherapy and antiangiogenic therapy

21 January 2018

1 reference

Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors

21 January 2018

1 reference

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

21 January 2018

2 references

21 January 2018

Tumor antigens recognized by T lymphocytes.

31 March 2020

1 reference

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

31 March 2020

1 reference

A listing of human tumor antigens recognized by T cells: March 2004 update

31 March 2020

1 reference

Escape from host-antitumor immunity.

31 March 2020

1 reference

Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection

31 March 2020

1 reference

Review: dendritic cell immunotherapy for melanoma.

31 March 2020

1 reference

Peptide-based vaccines for cancer immunotherapy

31 March 2020

1 reference

Targeting Bcl-2 and Bcl-X with nonpeptidic small-molecule antagonists

31 March 2020

1 reference

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

31 March 2020

1 reference

High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma

31 March 2020

1 reference

Tumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder Cancer

31 March 2020

1 reference

HLA-B35-restricted immune responses against survivin in cancer patients

31 March 2020

1 reference

Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin

31 March 2020

1 reference

Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals

31 March 2020

1 reference

Detection and quantification of CD8+ T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-?-elispot assay

31 March 2020

1 reference

Bcl-2 and apoptosis in chronic lymphocytic leukemia

31 March 2020

1 reference

The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients

31 March 2020

1 reference

The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses

31 March 2020

1 reference

CM101, a polysaccharide antitumor agent, does not inhibit wound healing in murine models

31 March 2020

1 reference

Expression of stress-induced MHC class I related chain molecules on human melanoma

31 March 2020

1 reference

Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report

31 March 2020

1 reference

Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.

31 March 2020

1 reference

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

31 March 2020

1 reference

Identification of novel survivin-derived CTL epitopes

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Spontaneous immunity against Bcl-xL in cancer patients

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identification of an HLA-A1 restricted CTL epitope from Mcl-1

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD1717

1 reference

12 August 2017

1 reference